IDEXX Laboratories Company Profile (NASDAQ:IDXX)

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

IDEXX Laboratories announced that its board has authorized a stock repurchase plan on Sunday, June 4th 2017, which authorizes the company to repurchase 3,000,000 outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to purchase shares of its stock through open market purchases. Stock repurchase plans are generally an indication that the company's management believes its stock is undervalued.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) issued its quarterly earnings data on Friday, April, 28th. The company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.61 by $0.16. The company earned $462 million during the quarter, compared to analysts' expectations of $455.10 million. IDEXX Laboratories had a net margin of 13.47% and a negative return on equity of 706.91%. The firm's quarterly revenue was up 10.7% on a year-over-year basis. During the same period in the previous year, the company earned $0.51 EPS. View IDEXX Laboratories' Earnings History.

IDEXX Laboratories is scheduled to release their next quarterly earnings announcement on Monday, July, 31st 2017. View Earnings Estimates for IDEXX Laboratories.

6 analysts have issued 12-month target prices for IDEXX Laboratories' shares. Their predictions range from $118.00 to $185.00. On average, they expect IDEXX Laboratories' stock price to reach $161.00 in the next year. View Analyst Ratings for IDEXX Laboratories.

Here are some recent quotes from research analysts about IDEXX Laboratories stock:

• 1. According to Zacks Investment Research, "IDEXX continues to demonstrate solid growth globally with strong international expansion. Management’s innovation-based global strategy is leading to its CAG Diagnostics growth. Solid organic revenue growth buoys optimism. Moreover, the company recently expanded its cloud technology portfolio by adding rVetLink to it. IDEXX’s last reported first quarter was also impressive with earnings and revenues growing year over year. The raised 2017 EPS guidance is also encouraging. Notably,  over the last six months, the company has been trading above the broader Medical Instruments industry. On the other hand, IDEXX's high dependence on third-party distributors and intense competition continue to pose threats. Moreover, with growing international expansion, the company's Companion Animal Diagnostics business is likely to suffer from adverse currency fluxes. The stock’s overvaluation also remains a concern." (7/19/2017)
• 2. Canaccord Genuity analysts commented, "Date and time of first dissemination: June 13, 2017, 12:32 ET Date and time of production: June 13, 2017, 12:32 ET Target Price / Valuation Methodology: IDEXX Laboratories – IDXX Valuation Framework. Our $180 PT uses a premium ~49x multiple on our 2018 adj. EPS estimate of $3.65 (+17% Y/Y). IDXX’ multiple is a premium to its 10-year median multiple of ~31x forward earnings (and 34x excluding the trough of the Great Recession), though we note the stock has traded north of 35x earnings in 2007, 2015, and since June 2016. Abaxis – ABAX Our $46 price target applies a 4.4x P/S multiple to our FY’18 revenue estimate of $240M and implies a 38x P/E multiple on our FY’18 adj." (6/13/2017)

Some companies that are related to IDEXX Laboratories include Actelion (ALIOF), Alexion Pharmaceuticals (ALXN), Fresenius Medical Care Corporation (FMS), Incyte Corporation (INCY), Zimmer Biomet Holdings (ZBH), Illumina (ILMN), Astellas Pharma (ALPMY), Edwards Lifesciences Corporation (EW), Cardinal Health (CAH), C.R. Bard (BCR), Cerner Corporation (CERN), Mylan N.V. (MYL), AmerisourceBergen Corporation (Holding Co) (ABC), Quintiles Transitional Holdings (Q), Lonza Group Ag (LZAGY), Laboratory Corporation of America Holdings (LH), BioMarin Pharmaceutical (BMRN) and Eisai Co., Ltd (ESALY).

IDEXX Laboratories' management team includes the folowing people:

• Jonathan W. Ayers, Chairman of the Board, President, Chief Executive Officer
• Brian P. McKeon, Chief Financial Officer, Executive Vice President, Treasurer
• Giovani Twigge, Chief Human Resource Officer, Corporate Vice President
• Jay Mazelsky, Executive Vice President
• Jacqueline L. Studer, Corporate Vice President, General Counsel, Corporate Secretary
• William T. End, Lead Independent Director
• Bruce L. Claflin, Independent Director
• Rebecca M. Henderson Ph.D., Independent Director
• Daniel M. Junius, Independent Director
• Lawrence D. Kingsley, Independent Director

IDEXX Laboratories' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Bank of Montreal Can (0.40%), Ardevora Asset Management LLP (0.27%), First Quadrant L P CA (0.24%), Howland Capital Management LLC (0.22%), Bourne Lent Asset Management Inc. (0.13%) and Harvey Investment Co. LLC (0.12%). Company insiders that own IDEXX Laboratories stock include Barry C Johnson, Brian P Mckeon, Daniel M Junius, Giovani Twigge, Jonathan W Ayers, Lawrence D Kingsley, Michael J Phd Williams, Rebecca M Henderson, Thomas Craig and William T End. View Institutional Ownership Trends for IDEXX Laboratories.

IDEXX Laboratories' stock was sold by a variety of institutional investors in the last quarter, including Capital Investment Services of America Inc., Ardevora Asset Management LLP, Russell Investments Group Ltd., First Quadrant L P CA, Meeder Asset Management Inc., Howland Capital Management LLC, Bourne Lent Asset Management Inc. and Headinvest LLC. Company insiders that have sold IDEXX Laboratories stock in the last year include Barry C Johnson, Brian P Mckeon, Daniel M Junius, Giovani Twigge, Jonathan W Ayers, Michael J Phd Williams, Rebecca M Henderson, Thomas Craig and William T End. View Insider Buying and Selling for IDEXX Laboratories.

IDEXX Laboratories' stock was bought by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Acadian Asset Management LLC, Meag Munich Ergo Kapitalanlagegesellschaft MBH, Mn Services Vermogensbeheer B.V., Oregon Public Employees Retirement Fund, Bedrijfstakpensioenfonds Voor DE Media PNO, National Pension Service and Aperio Group LLC. View Insider Buying and Selling for IDEXX Laboratories.

Shares of IDEXX Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of IDEXX Laboratories stock can currently be purchased for approximately $166.55.